南新制药连亏5年 2020年上市募12亿元西部证券保荐

Core Viewpoint - Nanjing New Pharmaceutical (688189.SH) has announced a projected loss for the fiscal year 2025, with significant declines in both revenue and net profit compared to the previous year [1] Group 1: Financial Performance - The company expects to achieve an operating income of between 120 million to 150 million yuan for 2025, representing a decrease of 113.28 million to 143.28 million yuan, or a decline of 43.03% to 54.42% year-on-year [1] - The projected net profit attributable to the parent company is expected to be a loss of between 160 million to 120 million yuan, which is a reduction in loss of 196.90 million to 236.90 million yuan compared to the previous year, equating to a year-on-year decrease in loss of 55.17% to 66.38% [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be a loss of between 165 million to 125 million yuan, with a reduction in loss of 193.53 million to 233.53 million yuan year-on-year, reflecting a decrease in loss of 53.98% to 65.14% [1] Group 2: Historical Financial Data - From 2021 to 2024, the net profits attributable to the shareholders of the listed company were -162 million yuan, -78.83 million yuan, -10.87 million yuan, and -357 million yuan respectively [2] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share and a total of 35 million shares issued [2] - The total amount raised from the initial public offering was 1.223 billion yuan, with a net amount of 1.135 billion yuan, exceeding the originally planned fundraising by 466 million yuan [2] Group 3: Equity Distribution - On July 16, 2022, the company announced a rights distribution plan, increasing its total share capital from 140 million shares to 196 million shares by distributing 0.4 shares for every share held [3] - On June 7, 2023, another rights distribution was announced, increasing the total share capital from 196 million shares to 274.4 million shares, again distributing 0.4 shares for every share held [3]